A recent FDA memorandum provides insight into the agency's thinking when it approved Biota Holdings Ltd.'s Relenza zanamivir dry powder for inhalation to treat influenza A and B - despite a 14-4 advisory committee vote against approval.

As approved, Relenza is intended to alleviate flu symptoms when administered twice daily in patients at least 12 years old who have been symptomatic for no more than two days.